Opioids in Chronic Non-Malignant Pain
Troubleshooting Drug Therapy Issues

October 2005
Objective Comparisons for Optimal Drug Therapy

Key Highlights
- Pain, the 5th vital sign, is often under-treated.
- Optimize use of both drug and non-drug interventions.
- Pain reduction and improved function, and not pain elimination are the goals of drug therapy. Those with CNMP must be helped to refocus on positive, incremental gains. Multiple visits are often required.
- Opioids have a role in select patients; carefully assess and use a treatment agreement to guard against abuse.
- Initiation of opioids doesn’t always mean a lifelong Rx.
- Consider long-acting formulations at regular intervals.
- Avoid meperidine (Demerol) use in general!
- Combination opioid/non-opioid drugs such as Tylenol #1 & Tylenol #3 are easily overused in chronic pain.

Introduction
Chronic non-malignant pain (CNMP) is complex involving physical, psychological, emotional, social, financial and spiritual factors. Non-drug modalities are critical in long-term optimal management. Non-pharmacological approaches include interdisciplinary programs, physiotherapy, cognitive / behavioral strategies, nutritional / exercise programs, etc. Regulations regarding the prescription of opioids attempt to encourage optimal opioid use when indicated while minimizing potential for misuse, abuse and diversion.

Recommended Reviews and Guidelines:
- Use of Opioid...Noncancer Pain...Canadian Pain Society, 2002
- Evidence-Based Recommendations...CNS-Pain-Canada, 2000
- General Principles...Pain Management with Opioids, SK
- Opioid Therapy for Chronic Pain, NEJM 2003
- Drug Class Review--Long-Acting Opioid(s)...Oregon, Apr 2005
- Issues in Opioid Management...Chronic Pain, Mar 2005
- Opioids...Chronic Pain, CSAM, Oct 2000
- Position Statement Opioid...Chronic Pain, APS, AAMP 1996
- Universal Precautions in Pain Medicine, Pain Medicine 2005
- Principles of Opioid Use in Chronic Noncancer Pain, CMAJ 2005

How strong is the evidence for opioids in CNMP?
- There is limited evidence supporting a role for opioids in CNMP. Most randomized control trials (RCT) have involved small numbers and short durations (<32 wks). Much of the literature consists of surveys, uncontrolled case series and open label follow up to RCTs.
- Systematic reviews suggest that opioids provide a short-term benefit with low risk of addiction and tolerable side effects when used appropriately in select patients. Whether opioids are beneficial in the long-term remains to be assessed. Trials exclude persons with history of past or current substance abuse. The NNT estimate is 3. In other words, for every 3 CNMP patients treated with an opioid, 1 will have at least a 50% reduction in pain.
- Drop out rates were around 30% in one analysis. Minor adverse events were common (63%); serious adverse events were rare. Long-term data is not available.
- Although there is no ceiling dose for strong opioids, lack of progressive pain relief with escalating doses in a opioid naïve patient may signal pain that is non-responsive to opioids. Most CNMP studies have used doses of morphine ≤ 200mg/day.

When should opioids be considered in CNMP?
- “In the absence of good evidence for a specific curative treatment for a given pain problem, a trial of long-term opioid therapy is a legitimate medical practice when a reasonable trial of other treatment modalities fails to improve comfort or function of the patient. There are very few types of pain that would absolutely preclude a trial of opioid therapy.”

Table 1: Definitions

| Addiction: LOSS of control over substance use WITH compulsive continued use despite harm. |
| Pseudoaddiction: drug seeking behavior mimicking addiction resulting from under-treatment of pain. |
| Dependence, physical: a state of adaptation resulting in drug class-specific withdrawal symptoms upon abrupt dose reduction, decreasing drug levels or antagonist administration. (not to be confused with addiction). |
| Tolerance: decreasing effect of a drug over time. |

Table 2: CAGE Questionnaire – Addiction Screening

| C – have you ever felt the need to Cut down on your drinking/drug use? |
| A – do you get Annoyed when others criticize your drinking/drug use? |
| G – have you ever felt Guilty about your drinking/drug use for any reason? |
| E – Eye-opener: Have you ever felt the need for a drink early in the morning to decrease hangover or withdrawal? |

One positive suggests caution; 2 or more suggests strong caution/need for vigilance.
Assessment for risk of addiction is important. Ask: “Have you or anyone in your family had problems with either alcohol or drugs?” Inquire into the quantity and frequency of alcohol or drug use to ensure it is within low risk parameters for the former, and as prescribed for the latter. The CAGE Questionnaire (see Table 2) is also useful. History of or risk factors for addiction is a complicating factor in pain management warranting co-management with an addiction medicine specialist.

Table 3: Universal Precautions in Pain Medicine

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Make a Diagnosis with Appropriate Differential</td>
</tr>
<tr>
<td>2.</td>
<td>Psychological Assessment Including Risk of Addictive Disorders (include discussion of urine drug testing)</td>
</tr>
<tr>
<td>3.</td>
<td>Informed Consent</td>
</tr>
<tr>
<td>4.</td>
<td>Treatment Agreement</td>
</tr>
<tr>
<td>5.</td>
<td>Pre/Post-Intervention Assessment of Pain &amp; Function</td>
</tr>
<tr>
<td>6.</td>
<td>Appropriate Trial of Opioid Therapy +/- Adjunct Agents</td>
</tr>
<tr>
<td>7.</td>
<td>Reassessment of Pain Score and Level of Function</td>
</tr>
<tr>
<td>8.</td>
<td>Periodically Review Pain Diagnosis and Comorbid Conditions, Including Addictive Disorders</td>
</tr>
<tr>
<td>10.</td>
<td>Document Assessment, Discussions and Progress</td>
</tr>
</tbody>
</table>

“Universal Precautions in Pain Medicine” is an approach to the assessment and management of chronic pain patients based on the assumption that one can not always determine who will become a problem user. Thus, it suggests a minimum level of care in assessing and managing risk. (See Table 3)

Preventing Abuse, Misuse and Diversion

- In pain patients without a history of substance abuse, prevalence of opioid addiction is thought to be low. This issue is not well studied in CNMP. {Reported opioid addiction rates in CNMP range from 3-19%12} 
- History of substance abuse complicates but does not contradict use of opioids in CNMP; however consultation with a specialist in pain & addiction is recommended.

In Saskatchewan, the Triplicate and/or the new PIP Rx programs are useful in identifying previous opioid usage.

- Consider faxing prescriptions; avoids alteration.
- Dated Prescriptions; notes expected duration of supply.

- Treatment Agreements provide a framework for abuse, misuse, diversion and addiction concerns by providing patient education, conveying treatment goals, encouraging patient adherence and proactively outlining how non-adherence will be handled. Patients at greater abuse risk, or with significant psychological component will require more structure / stricter boundaries in the agreement.

See Appendix A or www.RxFiles.ca for sample / customizable form.

How can one handle a CNMP patient who tests the boundaries of a treatment agreement?

This issue is inevitable arise when prescribing opioids in CNMP. For example, a patient may request just a few extra tablets, run out of drug early, or lose a prescription. If an agreement has previously been outlined and discussed, then the prescriber can note the issue, and respond accordingly. Options may include:

- make an exception but consider tightening boundaries
- document and warn the patient that a 2nd break in the agreement will result in:
  - urine drug testing
  - referral to addiction medicine
  - discontinuation of opioid therapy
  - discontinue opioid

Table 4: Red Flags – Aberrant Opioid Use

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Consider Discontinuation of Opioids / Specialist Referral</td>
<td></td>
</tr>
<tr>
<td>1.</td>
<td>Prescriptions from multiple physicians</td>
</tr>
<tr>
<td>2.</td>
<td>Frequent visits to emergency room requesting opioids</td>
</tr>
<tr>
<td>3.</td>
<td>Requests from patients from outside of local area</td>
</tr>
<tr>
<td>4.</td>
<td>Stolen or modification of prescriptions</td>
</tr>
<tr>
<td>5.</td>
<td>Extensive polypharmacy with CNS depressants and/or non-prescribed habituating substances</td>
</tr>
<tr>
<td>6.</td>
<td>Forgery, selling, stealing, or using other persons medications; tampering with prescriptions.</td>
</tr>
<tr>
<td>7.</td>
<td>Inquire into the quantity and frequency of alcohol or drug use to ensure it is within low risk parameters for the former, and as prescribed for the latter.</td>
</tr>
</tbody>
</table>

Reassess Regimen and/or Treatment Agreement

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Rapid escalation of dose in CNMP</td>
</tr>
<tr>
<td>2.</td>
<td>Frequent excuses for running out of medication</td>
</tr>
<tr>
<td>3.</td>
<td>Frequent loss of prescriptions and/or medications</td>
</tr>
<tr>
<td>4.</td>
<td>Frequent changes of the opioid prescribed</td>
</tr>
<tr>
<td>5.</td>
<td>Aversion to concurrent recommended treatments</td>
</tr>
<tr>
<td>6.</td>
<td>Request for Brand-name versus generic product</td>
</tr>
<tr>
<td>7.</td>
<td>Lack of request for adjunct analgesic refills</td>
</tr>
<tr>
<td>8.</td>
<td>Unsanctioned noncompliance with the regimen</td>
</tr>
</tbody>
</table>

Prescribing Considerations for Opioids in CNMP

- Pain reduction, improved function, & not pain elimination are the goals of drug therapy. {A pain score ≤ 4/10 may = success} 
- Thorough, ongoing assessments & pain scoring are useful! 
- Start at low-dose and titrate up gradually; “dose to effect” 
- Be cautious in the elderly; start low, go slow, but go 
- Remember neuropathic pain often requires higher doses 
- Use the oral route when available 

“PRN dosing may not be appropriate for every patient. In some cases it promotes patient autonomy while allowing the lowest dose of opioids. In others, such as patients with poor impulse control or “at risk” substance abuse patients, it may lead to inappropriate dose escalation and undermine attempts to stabilize the medication regimen”14

- Be aware of and prevent constipation (Table 6)
- Assess risk for nausea; provide antinauseant as needed
- Consider using a treatment agreement (patient contract)
- Document (assessment, drug trials, discussions, treatment plan, informed consent and/or treatment agreement)
- Ensure non-opioid therapies used when indicated for specific types of pain (see RxFiles Q&A Supplement: Pain – CNMP – Pharmacological Considerations – Table 1) 
- Ensure psychosocial, behavioral and physical exercise aspects of pain are dealt with concomitantly as opioid therapy alone may reinforce abnormal pain behavior 
- Adjust drug regimens to find the optimal balance between pain relief, function and side effects. (i.e. sedative/alcohol use) 
- Be aware that CNMP patients require higher doses of post-operative opioids, and experience fewer adverse effects15 
- Some patients will improve when taken off opioids
Long-acting opioids vs Short-acting opioids
- Long-acting regular opioids offer several advantages:
  - encourages patient compliance
  - allows tolerance to side effects (e.g. cognitive)
  - discourages the psychological dependence on opioids, often seen with short-acting PRN based regimens
- Short-acting opioids are useful for initial dose titration and in select patients prior to activities likely to worsen pain. Breakthrough “PRN” opioids may be suitable during the titration phase and in patients with flare-ups; however since some patients never obtain total relief, over-reliance on short-acting PRN opioids is common; minimize use.
- Chronic use of short-acting agents ≥2x/day, convert to long-acting.
- Be aware of the injection drug users’ preferences in your community and avoid those frequently diverted to the street (e.g. MS Contin, Dilaudid, OxyContin) in those at high risk or whose safety and security is in question. (Kadian may be more difficult to abuse; generic hydromorphone often has a lower street value)

Options for Apparent Tolerance to an Opioid
- If opioid is otherwise well tolerated, one may increase the dosage and monitor for increased effect
- If side effects develop, opioid rotation strategies may be effective although evidence is lacking. Switching to ½ - ⅔ of the usual equivalent dose of another opioid is recommended to allow for incomplete cross-tolerance.
- Adding or modifying adjunct agents may also be effective, depending on the pain condition treated.

What Role does Methadone have in CNMP?
- Methadone may be useful in opioid rotation strategies. Its potential but unproven NMDA antagonist effect may have benefits in neuropathic pain. It may be particularly useful in patients who have concomitant pain and addiction conditions. Due to risks associated with its long half-life a special authorization to prescribe is required in SK (List available from the College of Physicians and Surgeons of SK; SK drug plan covers for palliative pain use only.)

Why Avoid Meperidine (DEMEROL) in CNMP? [ISMP]
- Its very short duration results in early recurrence of pain, need for frequent dosing, and increased abuse potential
- Normeperidine, a toxic metabolite may accumulate with chronic use causing delirium, seizures and myoclonic jerks.
- The oral formulation has very poor absorption
- Evidence does not support any advantage in pancreatitis
- RQHR Regina recently removed oral form from formulary
- Anileridine (LERITINE) has similar disadvantages

Problems with Combination Drugs (e.g. Tylenol #3)
- Due to the nature of chronic pain, it is not uncommon to see overuse of combination products. Their short duration of action and low potency makes them poor long-term choices.
- Risk of acetaminophen toxicity increases with excessive single doses or chronic use of usual high doses. In addition, psychological dependence is reinforced by the frequent use.
- Minimize reliance on opioid/acetaminophen (e.g. Tylenol #3, Transcor) combination products in the long-term treatment plan.
- Ensure daily dose of acetaminophen does not exceed 4g (some literature suggests limiting chronic use to 2.4-3.2g/d)
- Assess for overuse of OTC combinations (e.g. Tylenol #1)

Dose Dumping - Long-acting Formulations & Alcohol
- The potential for “dose dumping” with long-acting opioids, especially once-daily formulations, should be considered and patients cautioned to take only with water.
- {PALLADONE, a once-daily long acting formulation of hydromorphone, was recently removed from the US market because it was found to have peak concentrations up to 6X greater when given with alcohol compared to water.}

Transdermal Fentanyl (DURAGESIC) – Cautions
- Although potency can vary widely, 25mcg/hr fentanyl patch is roughly equivalent to 90mg/day oral morphine. This high potency has caused serious life-threatening toxicity, especially in opioid naïve patients, and kids <18yrs.
- Patients with poor response to codeine e.g. Tylenol #3 or tramadol may be non-metabolizers and considered opioid naïve.
- Any adverse events or overdose effect is prolonged due to the long-acting reservoir of drug in the skin. Corticosteroid sprays, may be useful to reduce skin irritation.
- Rate of absorption is much more rapid with heat (e.g. hot tubs, heat blankets, exercise, fever). This can increase risk of toxicity and/or shorten duration of patch effectiveness.
- Delayed effect of any dosage changes limit the usefulness of this agent in individuals with frequent variations in their pain intensity. Due to the time required for plasma concentrations to stabilize, dosage adjustments should not be made any more frequently than q3-6days.

Opioid Withdrawal
- Gradual withdrawal of opioids will minimize the sympathetic rebound that otherwise occurs (see Table 5); wean the daily dose by up to 10-20% per day or taper opioids over several weeks to minimize withdrawal.
- Clonidine may be used in abrupt discontinuation:
  - 5-15mcg/kg/day in divided doses x 7-14 days, then taper (e.g. 0.1mg TID & 0.2mg HS x2wks, then taper over 2wks)
  - monitor for withdrawal and orthostatic hypotension
  - taper clonidine to avoid rebound hypertension
- Patients with strong addiction history or risk require special consideration and management by a specialist.

Table 5: Opioid Toxicity vs Withdrawal
<table>
<thead>
<tr>
<th>Opioid Toxicity</th>
<th>Opioid Withdrawal {flu-like}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confusion, agitation, visual defects, vivid dreams or nightmares, hallucinations, myoclonic jerk</td>
<td>opioid craving, anxiety, restlessness, yawning, perspiration, lacrimation, rhinorrhea, insomnia, mydriasis, piloerection, tremors, hot/cold flashes, hypertension, tachycardia, fever, tachypnea, vomiting, diarrhea, muscle aches</td>
</tr>
<tr>
<td>Severe, acute: respiratory depression; sudden severe sedation (reversed by naloxone)</td>
<td>unpleasant but not life-threatening</td>
</tr>
</tbody>
</table>

We would like to acknowledge the following contributors and reviewers:

Physics, Dr. A. Chakravarti (SHR-Anaesthesia/Cancer Pain Centre), Dr. P. Butt (SHR-Family Medicine/Methadone Clinic), Dr. K. Ståke (SHR-PallCare), Dr. B. Bernacki (SHR-Rehab), Dr. K. Shaw (CPSS), Dr. F. Remillard (U. of S., C. of Pharmacy), Dr. T. Laubscher (SHR-Family Medicine), Dr. P. Harris (Regina); Dr. M. Montibrand (Regina), M. Lawrence (RQHR-Pharmacy), S. Poulin (RQHR-Pharmacy), Dr. M. Lang (RQHR-Anaesthesia), Dr. J. Leszczynski (RQHR-Rehab) & the RxFiles Advisory Committee.

L. Rieger, B. Jensen

DISCLAIMER: The content of this newsletter represents the views, narratives and experiences of the authors and those trained in the education of Saskatchewan Health Region (SHR). Neither the authors nor Saskatchewan Health Region nor any other party who has been involved in the preparation or publication of this work warrants or represents that the information contained herein is accurate or complete, and they are not responsible for any errors or omissions or for the result obtained from the use of such information. Any use of the newsletter is purely for educational purposes and any mention or discussion in this newsletter does not represent any responsibility of SHR, its employees, servants or agents. Readers are encouraged to seek the advice of their healthcare providers for any medical condition they may have.

Copyright 2005 – RxFiles, Saskatchewan Health Region (SHR) www.RxFiles.ca
A Few Thoughts on Adjunct Agents

- A variety of adjunct agents should be considered in specific pain conditions. See RxFiles Supplement Chart - Pain Conditions – Specific Drug Therapy Options – Table 1. For neuropathic pain, TCAs have been the most effective agents NNT=2-3, followed by anticonvulsants NNT=3-5, or venlafaxine. SSRIs have sometimes been effective NNT=7. TCAs: Nortriptyline is often preferred or a good alternative when amitriptyline is not tolerated. Encourage patients to be patient and allow for an adequate trial. Dose may be titrated up to effective dose gradually to reduce side effects.

- Gabapentin has good evidence for diabetic neuropathy, and post-herpetic neuralgia but remember that the dose required is usually in the 900-1800mg/day range. Adding to morphine produced a small benefit of questionable clinical significance in neuropathic pain patients. One may consider weighting the dose towards nighttime (e.g. 300mg BID & 600mg HS).

Table 6: Opioid Adverse Effects

- **Nausea & Vomiting (N&V)**
  - Reassure that tolerance usually develops in <1-2 wks
  - Titrate opioid dose slowly & consider short-term prochlorperazine 5-10mg q6h PRN, haloperidol 0.5-1mg BID PRN, metoclopramide 10-50mg PRN, domperidone 5-10mg TID AC (transdermal scopolamine for dizziness & secretions)
  - prophylactic use if patient gives history of N&V
  - May consider other routes of administration (e.g. patch)

- **Histamine - urticaria, pruritis**
  - Reassure that tolerance usually develops (true allergy rare)
  - Utilize adjunct therapy that may allow ↓ dose
  - Premedicate with antihistamine e.g. diphenhydramine 25-50mg (rantside 150mg HS or Q12h may also be useful adjunct)
  - Switch opioids. (if class effect, nalbuphine solution has been used)

- **Sweating**
  - GTA sweating: glycopyrrolate, scopolamine or clomidrine

- **Dry Mouth**
  - Regular sips of water, sugarless gum etc.
  - Consider saliva substitute (e.g. ORAL BALANCE GEL)

Options for Opioid Induced Constipation

- **Diet**
  - encourage fibre (bran 1 cup All Brans), flax 1 tablespoon seeds, prunes/prune juice 1 cup, water 4-6 cups, & a balanced diet

- **Exercise**
  - regular activity as tolerated

Step 1 Oral Laxatives

- Senna 1-2tablets at HS=2 BID (max ~8 tabs/day) or Bisacodyl 1-tablets at HS (max ~8 tabs/day) (Decussate 1 BID stool softerner only, minimal effect)
- MOM 30-60ml OD (Cf if renal failure); Sorbitol 70% 30ml OD-QID; Lactulose 15ml BID, max 30ml TID

Step 2 Laxatives

- May combine step 1 agents; if no bowel movement: Mg Citrate, Fleet enema, Pegylite or GoLYtely 25ml OD-BID PRN

Step 3

- Consult physician if several days (96+hrs), pain, severe bloating. [temporarily ↓ opioids]

Opioid Prescribing / CNMP Tools

1) Treatment Agreement: http://www.paincare.ca/Documents/En/Patient_Treatment_Agreement.pdf

2) Mental Status Assessment (Folstein Mini Mental): http://www.paincare.ca/Documents/En/Mental_Status_Examination.pdf


References:

6. Long-Acting Opioids – Findings from a Systematic Review
- Fentanyl vs morphine LA, n=686; heterogeneous CNMP : equivocal results:
  - fentanyl good pain control (40% vs 19%) & marginally better pharmacological functioning score (28.6 vs 27.4, p=0.004) & mental health score (44.4 vs 43.1, p=0.03)
  - morphine – lower withdrawal rate (9% vs 16%)
  - post-hoc analysis benefit in fentanyl group in subset who had “bad” or “very bad” score before on previous morphine: no difference in score for those who were opioid naive
  - morphine - OD vs OD vs BID vs placebo 2045; n=239, 0A
  - no difference between morphine regimens
  - morphine greater efficacy than placebo
  - LA opioids vs placebo: n=664; n=239; heterogeneous CNMP
  - superior efficacy for LA opioids over placebo; no difference between opioids, data regarding whether LA preparations have fewer adverse events was equivocal
  - No data to support that any LA opioid is superior to any other in any CNMP subgroup (population or adverse effects)


A Pain & Medication Diary is useful to track patterns of pain occurrence and the time, dosages, and side effects of analgesics used, assisting in therapy adjustments.